Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y

22.04.25 18:14 Uhr

Werte in diesem Artikel
Aktien

172,82 EUR 3,50 EUR 2,07%

Indizes

5.287,8 PKT 129,6 PKT 2,51%

Danaher Corporation’s DHR first-quarter 2025 adjusted earnings of $1.88 per share beat the Zacks Consensus Estimate of $1.62. However, the bottom line decreased 2.1% year over year.Danaher reported net sales of $5.74 billion, which beat the consensus estimate of $5.56 billion. However, the metric decreased 1% year over year, owing to the lackluster performance of the Diagnostics and Life Sciences segments.DHR’s core sales were flat in the quarter. Acquisitions had a positive impact of 0.5% on quarterly sales while foreign-currency translations had an adverse impact of 1.5%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)DHR’s Segmental DiscussionRevenues from the Life Sciences segment totaled $1.68 billion, down 3.5% year over year. We expected the segment’s revenues to be $1.62 billion. Core sales decreased 4% year over year. Acquisitions had a positive impact of 2% on segmental sales while foreign-currency translations had a negative impact of 1.5%. Operating profit was $201 million, down 14.5% year over year. Revenues from the Diagnostics segment totaled $2.44 billion, down 3.1% year over year. Our estimate for revenues was $2.35 billion. Core sales decreased 1.5% year over year, while foreign currency had an adverse impact of 1% on sales. Acquisitions/divestitures impacted sales by 0.5%. Operating profit was $718 million, down 13.5% on a year-over-year basis.Revenues from the Biotechnology segment totaled $1.61 billion, up 6% year over year. Our estimate was $1.59 billion. Core sales increased 7% year over year while foreign-currency translations had an adverse impact of 1%. Operating profit was $441 million, up 35.7% year over year.Danaher Corporation Price, Consensus and EPS Surprise Danaher Corporation price-consensus-eps-surprise-chart | Danaher Corporation QuoteDanaher’s Margin ProfileIn the first quarter, Danaher’s cost of sales decreased 3.4% year over year to $2.2 billion. Gross profit of $3.51 billion increased 0.7% year over year. The gross margin was 61.2% compared with 60.2% in the year-ago quarter.Selling, general and administrative expenses of $1.86 billion recorded an increase of 2.8% on a year-over-year basis. Research and development expenses were $379 million, up 3% year over year.Danaher’s operating profit decreased 2.9% year over year to $1.27 billion. Operating margin contracted to 22.2% from 22.6% in the year-ago quarter.DHR’s Balance Sheet and Cash FlowExiting the first quarter, DHR had cash and equivalents of $2 billion compared with $2.1 billion at 2024-end. Long-term debt was $16 billion at the end of the quarter compared with $15.5 billion at the end of December 2024.Danaher generated net cash of $1.3 billion from operating activities in the first three months of 2025 compared with $1.7 billion in the previous year’s comparable period. Capital expenditures totaled $245 million in the same period, down 15.8% year over year. Adjusted free cash flow decreased 27% year over year to $1.06 billion in the first three months of 2025.In the same period, DHR paid out dividends of $194 million, up 9.6% on a year-over-year basis.Danaher’s OutlookFor the second quarter, Danaher expects adjusted core sales from continuing operations to increase in the low single digits on a year-over-year basis.The metric is anticipated to increase approximately 3% on a year-over-year basis in 2025. The company expects adjusted earnings to be $7.60-$7.75 per share.DHR’s Zacks RankThe company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Performance of Other CompaniesAZZ Inc. AZZ came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.95. This compares with earnings of $0.93 per share a year ago.AZZ reported revenues of $351.88 million, missing the Zacks Consensus Estimate by 3.77%. This compares with year-ago revenues of $366.5 million. Valmont Industries VMI reported revenues of $969.31 million in the first quarter of 2025, declining 0.9% on a year-over-year basis. EPS of $4.32 for the same period compares with $4.32 a year ago.The reported revenues compare with the Zacks Consensus Estimate of $975.6 million. The company delivered an EPS surprise of 1.89%, with the consensus estimate being $4.24.Pentair plc PNR came out with quarterly earnings of $1.11 per share in the first quarter of 2025, beating the Zacks Consensus Estimate of $1.01. This compares with earnings of $0.94 per share a year ago.Pentair posted revenues of $1.01 billion for the quarter, surpassing the Zacks Consensus Estimate by 2.68%. This compares with year-ago revenues of $1.02 billion.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Valmont Industries, Inc. (VMI): Free Stock Analysis Report Danaher Corporation (DHR): Free Stock Analysis Report AZZ Inc. (AZZ): Free Stock Analysis Report Pentair plc (PNR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Danaher und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Danaher

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Danaher

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Danaher Corp.

Wer­bung

Analysen zu Danaher Corp.

DatumRatingAnalyst
19.07.2019Danaher BuyNeedham & Company, LLC
30.05.2019Danaher OutperformWolfe Research
17.04.2019Danaher BuyNeedham & Company, LLC
28.02.2019Danaher BuyNeedham & Company, LLC
03.01.2019Danaher BuyNeedham & Company, LLC
DatumRatingAnalyst
19.07.2019Danaher BuyNeedham & Company, LLC
30.05.2019Danaher OutperformWolfe Research
17.04.2019Danaher BuyNeedham & Company, LLC
28.02.2019Danaher BuyNeedham & Company, LLC
03.01.2019Danaher BuyNeedham & Company, LLC
DatumRatingAnalyst
21.04.2017Danaher Sector PerformRBC Capital Markets
27.05.2016Danaher Sector PerformRBC Capital Markets
22.04.2016Danaher Sector PerformRBC Capital Markets
27.01.2016Danaher Sector PerformRBC Capital Markets
23.10.2015Danaher Sector PerformRBC Capital Markets
DatumRatingAnalyst
14.12.2006Danaher underweightPrudential Financial

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Danaher Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen